|President GH Bush just treated with a 'procedure' to help his breathing. Hope it was PneumRx.|
|Yes of course it was Clinton who is anti pharma and has been for a quarter of a century.Pointing out that the drug companies spend far too much entertaining customers and charge excessively high prices.Trump,however,also indicated during the electioneering that he was happy to entertain a tougher pricing regime for pharma companies.One's got to assess whether the tougher climate isn't potentially discounted in a sector that has lagged the broader market.|
|Correct me if I am wrong, but wasn't it Hillary Clinton who was expected to be bad for Pharma?
In August, Pharmaceutical shares came under intense pressure after reports about Clinton complaining about excessive price increases and promising of a clampdown on excessive charges.
In fact Clinton had never been considered a friend of big pharma which possibly explains why over a third of her campaign contributions came from pharma companies trying to buy influence.|
|Yes I suppose we're going to have to get used to Trump impacting perception surrounding the sector.It isn't going to go away anytime soon.Donald doesn't seem to be very happy with large swathes of society extending from the media,to the security services to foreigners.It could all become rather exhausting to have such a feral character bestriding the world stage twittering like a giant colossus.|
|The TRUMP effect!|
|First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system
10 January 2017
BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system. The EKOS® system includes an ultrasonic device that uses acoustic pulses to quickly and safely dissolve blood clots and restore blood flow in patients with PE, deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).
Blood clots are tightly bound together in a fibrous mesh called fibrin. Fibrin blocks the flow of thrombolytic drugs, requiring a higher drug dose to be effective.The EKOS®system uses acoustic pulses to unwind and thin fibrin to expose drug receptor sites, allowing the drug to reach deeper into the clot, accelerating absorption and helping to dissolve the clot faster and with less thrombolytic.1,2
Dr. Luk Wing Hang, Consultant Radiologist at the Princess Margaret Hospital, who performed the procedure on one of the patients, said: “Prevalence of fatal PE was 0.21% (1964-74), 1.08% (1975-79), 1.83% (1980-84), 2.77% (1985-90), and 4.7% (1990- 94) and the trend has been found to be increasing year after year with the percentage approaching western countries’ occurrence rate”. In addition, Dr. Luk updated that the patient treated with the EKOS® system was clinically stabilized with no desaturation or shortness of breath and their blood pressure was back to normal.
Later, in the same week, another case of submassive pulmonary embolism was treated just eight miles away at the Prince of Wales Hospital, where Interventional Cardiologist Prof. Bryan P. Yan was the treating physician. “The EKOS® system enables much lower and safer doses of thrombolytic drugs to be used which significantly reduces the risk of major bleeding. The device is currently the only US FDA cleared, minimally invasive endovascular therapy for PE” Our patient’s condition was improved significantly after 12 hours of ultrasound assisted thrombolysis with the EKOS® system. His breathing and blood pressure were improved and his grossly dilated right heart returned to nearly normal size and he was successfully discharged home” added Prof. Bryan P. Yan.
James Glasgow, General Manager at BTG Asia, said: “I am pleased to introduce our ultrasonic catheter device to the Hong Kong market to improve the treatment of severe blood clots. BTG is committed to delivering a better standard of care for patients who suffer from PE, DVT and PAO, with improved outcomes and lower associated risks through the development of minimally invasive therapies like the EKOS® system.”
The EKOS® system is now commercially available to hospitals in Hong Kong. The EKOS®system is distributed in Hong Kong by PPL Medical Limited which has the rich experience of distributing life-saving medical devices and equipment in Hong Kong and Macau for over 35 years.
About Pulmonary Embolism
Pulmonary Embolism (PE) is a condition where one or more clots break off or travel from existing venous clots in the legs or arms and travel in the circulation, getting trapped in the lung, where they block the ability of blood to get to some areas of the lungs and receive oxygen. This may lead to a strain on the heart’s ability to pump blood through the lungs which can then lead to heart failure and/or cardiovascular collapse. PEs can be immediately fatal, but if PE can be diagnosed and appropriate therapy started, the mortality can be reduced from approximately 30 percent to less than 10 percent.7
About the EkoSonic® Endovascular System
The EKOS® system uses ultrasonic waves in combination with clot-dissolving thrombolytic drugs to effectively dissolve clots and restore healthy heart function and blood flow.
In clinical studies EKOS®therapy has been shown to speed time-to-clot dissolution, increase clot removal and enhance clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy.4,5EKOS®therapy requires significantly shorter treatment times and less thrombolytic compared to standard catheter-directed drug therapy6, lowering the risk of bleeding and other complications.2,3
Reference materials as the remarks in the press release:
1Chau KY, Yuen ST, Ng TH, Ng WF. An autopsy study of pulmonary thromboembolism in Hong Kong Chinese. Pathology 1991;23:181-4. Chau KY, Yuen ST, Wong MP. Clinicopathological pattern of pulmonary thromboembolism in Chinese autopsy patients: comparison with Caucasian series. Pathology 1997;29:263-6.
2Kucher, N., et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, Vol. 129, No. 4, 2014, 479–486.
3Piazza G et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. The SEATTLE II Study. J Amer Coll Cardiol: Cardiovasc Interventions 2015; 8(10):1382-1392.
4Lin, P., et al., “Comparison of Percutaneous Ultrasound-Accelerated Thrombolysis versus Catheter-Directed Thrombolysis in Patients with Acute Massive Pulmonary Embolism.” Vascular, Vol. 17, Suppl. 3, 2009, S137–S147.
5Lin, P., et al., “Catheter-Directed Thrombectomy and Thrombolysis for Symptomatic Lower-Extremity Deep Vein Thrombosis: Review of Current Interventional Treatment Strategies.” Perspectives in Vascular Surgery and Endovascular Therapy, 2010, 22(3): 152–163.
6Parikh, S., et al., “Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience.” Journal of Vascular and Interventional Radiology, Vol. 19, Issue 4, April 2008, 521–528.
7Banovac, R et al., J Vasc Interv Radiol, 2010; 21:44-53.
For further information contact:
Hayley Senior, Media Relations Manager +44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director +44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
Chris Gale, Vice President +1-646-695-2883; Mobile: +1-203-570-4681
BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.
Back to press releases|
|Can you expand fhmktg|
|China here we come!|
|Here is another industry feedbackhttp://www.vasculardiseasemanagement.com/blog/five-reasons-utilize-varithena-varicose-vein-treatment|
|Still have 18 months to put the legs back on the road lol|
|You forgot to tell us the name of this wonderful product, corresponding to VHS, which you are suggesting is taking all the sales away from Varithena.|
|Varithena is a "Betamax" of sorts.Do you remember Sony's Betamax that got swept aside by an arguably inferior but better marketed VHS format.So with Varithena,a product in which the company continues to vest great faith but disappoints the market in its uptake.This is really the debate here.The company believes in its product but must accept that it's had real snags in achieving desired uptake.Betamax didn't mean that Sony was a bad company,in fact,it confirmed the company as being ahead of the curve technologically.(Sony was naive when it came to launching a video tape that could only record for an hour and it failed to nurture the prerecorded sales market.)BTG has been naive in its own way too but it's too early to damn Varithena as an irretrievable disappointment.|
|I will give it to 2020 , still has potential to surprise on the upside . If not there maybe bid interest giving the current exchange rate . However it is very much looking like the exchange difference is starting to close.
If they want to achieve their targets then fully suspect they need a £200 -400 million bolt on . The issue maybe that the exchange rate changes in the last 6 months have put that on the back burner for the time being .So a lot to play for depending on the currency exchange situation .
varenthena has highlighted that they are not good at bringing new products to market .
I would really like to know how the partnership with Phillips is progressing , never heard anything from that direction . It could be a game changer.|
|I reckon there is 0 chance of increased frequency trading updates as the regulatory authorities want to discourage short-term trading and no longer require pre-close trading statements. If the authorities will connive at the lack of disclosure what chance does the private investor stand. I would have thought that the authorities' position would have a possible unintended consequence whereby it reduces the opportunities for directors to trade and avoid the charge of insider trading.
Varithena has been very disappointing and while I am in profit I do wish I'd taken the money at £8, when held off because I thought it would be the real making of the company. My inclination is to sell.|
|05 Jan 17 Panmure Gordon Buy 737.00 Resumes
05 Jan 17 Jefferies International Buy 860.00 Reiterates
04 Jan 17 JP Morgan Cazenove Neutral 790.00 Reiterates
IMO BTG is again in traders hands and they are able to move share price up and down like they want and when they want shaking out retail investors and scaring them to sell.
Like I wrote before management is responsible for Verethena failure and dont understand that they are and only they can improve situation partnering with big distribution company , which will be able to get smooth reimbursments for doctors and patients and do marketing on tv and new and old media.There are basicly no or very little marketing for Varethena yet.I asked doctors in New York City and only one new about Varethena .
Hope that management will do volunterally trading updates ofter than they do now and will explain what they do . Twice a year updates is not enough IMO.
Any thoughts ? What you guys think ?
What is your views and opinions ?
What is your ratings BUY , SELL or Hold ?|
|JPM from yesterday I think.
"BTG we remain Neutral, as although we see a strong topline
performance for Interventional Medicine, we still see some downside to
consensus expectations for 2018 and beyond, M&A needed to sustain the
double digit topline aspiration"|
|Well that little burst didn't last long!|
|Let's see if the Yanks have a nibble!|
|It's obvious that pesky Varithena is holding BTG down.
Erm, isn't it?
|I see why BTG is up this morning........... Next mild resistance at approx 650p.
BTG PLC BTG Panmure Gordon Buy 618.25 588.50 - 737.00 Resumes
SP Target 737p
BTG PLC BTG Jefferies International Buy 618.25 588.50 860.00 860.00 Reiterates
Sp Target 860p.
present share price = 624p + 6% on the day.|
|on the wings of Love . Looks like the boys have had enough of the selling now and want it higher again.|
|Buy recommendation this morning target 860|
|any idea why the share price is up?|
|PANMURE RESUMES BTG WITH 'BUY' - TARGET 737 PENCE|